New gene therapy strategy uses the brain's own glymphatic transport system for drug delivery

https://www.news-medical.net/news/20260708/New-gene-therapy-strategy-uses-the-brains-own-glymphatic-transport-system-for-drug-delivery.aspx A new study describes a gene therapy strategy that uses the brain's own glymphatic transport system to distribute engineered viral vectors throughout the brain. The approach addresses two major challenges in neurological medicine-reaching therapeutic targets behind the blood-brain barrier and limiting unwanted effects elsewhere in the body-and could pave the way for new treatments for diseases including multiple sclerosis, Huntington's disease, and rare childhood white matter disorders.

New study identifies shared risk factors for breast cancer and atrial fibrillation

https://www.news-medical.net/news/20260708/New-study-identifies-shared-risk-factors-for-breast-cancer-and-atrial-fibrillation.aspx Alcohol use and smoking were linked to breast cancer and atrial fibrillation/flutter in women ages 55 years and older in multiple regions of the world, according to new, independent research published today in the Journal of the American Heart Association, an open access, peer-reviewed journal of the American Heart Association.

Yogurt, prebiotics, and probiotics link to lower colorectal cancer odds in U.S. adults

https://www.news-medical.net/news/20260708/Yogurt-prebiotics-and-probiotics-link-to-lower-colorectal-cancer-odds-in-US-adults.aspx A large U.S. nutrition analysis suggests that microbiota-friendly foods and supplements may be associated with a lower colorectal cancer burden, while highlighting the need for stronger long-term studies. In a recent study appearing as an Article in Press in the journal Nutrition & Diabetes, researchers examined the association between any prebiotic, probiotic, or yogurt intake and colorectal cancer (CRC).

Why Most Animal Viruses Never Become Human Pandemics

https://www.news-medical.net/health/Why-Most-Animal-Viruses-Never-Become-Human-Pandemics.aspx From receptor mismatch to risky human-animal interfaces, this article explains why spillover is common but true pandemic emergence remains rare. Humans are constantly exposed to animal viruses through farming, wildlife contact, and the environment; however, most animal viruses never reach pandemic potential. Successful spillover events are uncommon, as viruses must navigate complex biological, ecological, and evolutionary barriers before human-to-human transmission can occur. In the spillover cascade, an infected reservoir host must shed enough virus, the virus must survive or be carried to a susceptible human, and infection must then progress to onward transmission; failure at any one step can stop emergence.1,5 These barriers are also shaped by human behavior, land-use change, wildlife trade, farming systems, and other interfaces that determine how often people encounter infectious animals or contaminated environments.

Immune Effector Cell-Associated Enterocolitis in Relapsed/Refractory Multiple Myeloma Treated With Ciltacabtagene Autoleucel by Madaline Spencer| Published on: Jun 18, 2026

Immune Effector Cell-Associated Enterocolitis in Relapsed/Refractory Multiple Myeloma Treated With Ciltacabtagene Autoleucel by Madaline Spencer| Published on: Jun 18, 2026 Yi Lin, MD, PhD, Hematologist/Oncologist at Mayo Clinic, discusses immune effector cell-associated enterocolitis (IEC-EC) in patients with relapsed/refractory multiple myeloma (R/R MM) treated with ciltacabtagene autoleucel (cilta-cel). https://checkrare.com/immune-effector-cell-associated-enterocolitis-in-relapsed-refractory-multiple-myeloma-treated-with-ciltacabtagene-autoleucel/

Pediatric Adrenal Insufficiency: Etiology, Diagnosis, and Management by CheckRare Staff| Published on: Jun 11, 2026

Pediatric Adrenal Insufficiency: Etiology, Diagnosis, and Management by CheckRare Staff| Published on: Jun 11, 2026 Mitchell Geffner, MD, Co-Director, Congenital Adrenal Hyperplasia Clinic, and Ron Burkle Chair, Center for Endocrinology, Diabetes, and Metabolism, Children’s Hospital of Los Angeles, discusses the etiology, diagnosis, and management of pediatric adrenocortical insufficiency. https://checkrare.com/pediatric-adrenal-insufficiency-etiology-diagnosis-and-management/

Are All Cancers Rare Cancers? The Need for Better Classification Systems by Madaline Spencer| Published on: Jul 2, 2026

Are All Cancers Rare Cancers? The Need for Better Classification Systems by Madaline Spencer| Published on: Jul 2, 2026 Chadi Nabhan, MD, Hematologist and Oncologist, Chief Medical Officer at Ryght AI, and Vivek Subbiah, MD, Professor of Medicine at Stanford University and Executive Medical Director of Novel Therapies & Clinical Trial Network at Stanford Health Care, discuss the need for better classification systems in precision oncology. https://checkrare.com/are-all-cancers-rare-cancers-the-need-for-better-classification-systems/

Mental Health Challenges and Care Gaps in Patients With Lipodystrophy by Madaline Spencer| Published on: Jul 7, 2026

Mental Health Challenges and Care Gaps in Patients With Lipodystrophy by Madaline Spencer| Published on: Jul 7, 2026 Kate Stratton, Executive Director of Lipodystrophy United, discusses mental health challenges and care gaps in patients with lipodystrophy. https://checkrare.com/mental-health-challenges-and-care-gaps-in-patients-with-lipodystrophy/

A Patient’s Diagnostic Journey With Congenital Adrenal Hyperplasia by Madaline Spencer| Published on: Jul 8, 2026

A Patient’s Diagnostic Journey With Congenital Adrenal Hyperplasia by Madaline Spencer| Published on: Jul 8, 2026 Melanie Gander, mother of a son with congenital adrenal hyperplasia (CAH), and Ambassador with Neurocrine Biosciences, discusses her son’s diagnostic journey with congenital adrenal hyperplasia (CAH). https://checkrare.com/a-patients-diagnostic-journey-with-congenital-adrenal-hyperplasia/

Equal stakeholders: how FESCA is preparing patient advocates to reshape scleroderma research 6 July 2026

https://rarerevolutionmagazine.com/equal-stakeholders-how-fesca-is-preparing-patient-advocates-to-reshape-scleroderma-research/ The Federation of European Scleroderma Associations (FESCA) is working to move patient involvement in research from token gesture to genuine partnership. Sue Farrington, president, FESCA and chief executive of Scleroderma and Raynaud’s UK (SRUK), and Ilaria Galetti, vice president of FESCA, share how training, language and structural shifts can turn a patient voice into research that reflects their greatest needs Written by Nicola Miller, RARE Revolution Interview with Sue Farrington, president FESCA, chief executive, Scleroderma and Raynaud’s UK (SRUK) and, and Ilaria Galetti, vice president, FESCA

Prevalence of adverse childhood experience items: a systematic review and meta-analyses Prof, Dr Sheri Madigan, PhDa,b Send email to sheri.madigan@ucalgary.ca ∙ Carole A Lunney, MAa ∙ Anh Ly, MAa ∙ Prof R M Pasco Fearon, PhDc ∙ Glorianna Sin, BSc (Hons)a ∙ Alanna Kaser, BSc (Hons)a ∙ et al.

Prevalence of adverse childhood experience items: a systematic review and meta-analyses Prof, Dr Sheri Madigan, PhDa,b Send email to sheri.madigan@ucalgary.ca ∙ Carole A Lunney, MAa ∙ Anh Ly, MAa ∙ Prof R M Pasco Fearon, PhDc ∙ Glorianna Sin, BSc (Hons)a ∙ Alanna Kaser, BSc (Hons)a ∙ et al. https://www.thelancet.com/journals/lanpub/article/PIIS2468-2667(26)00077-0/fulltext?dgcid=hubspot_update_feature_updatealerts_lanpub&utm_campaign=update-lanpub&utm_medium=email&_hsenc=p2ANqtz-_hRMu2oaHQWv5rKxx5MlaUs84IfCASalvfLdlLGYDNSVNNIQrYvO50ZQIoYUVVtl9xfgo5N0UlhalAOzmaRb3Egk8zKg&_hsmi=427330715&utm_content=427086455&utm_source=hs_email

Editorial e417 Protecting childhood: a pressing priority The Lancet Public Health +...

Editorial e417 Protecting childhood: a pressing priority The Lancet Public Health https://www.thelancet.com/journals/lanpub/issue/vol11no7/PIIS2468-2667(26)X2006-0

Adverse childhood experiences in children and youth experiencing homelessness: a systematic review and meta-analysis Kirsten Gehrenbecka Send email to kirsten.gehrenbeck@charite.de ∙ Prof Felix Bermpohl, MDa ∙ Karl Deutschera ∙ Prof Seena Fazel, MDb ∙ Prof Stefan Gutwinski, MDa,† ∙ Stefanie Schreiter, MD

Adverse childhood experiences in children and youth experiencing homelessness: a systematic review and meta-analysis Kirsten Gehrenbecka Send email to kirsten.gehrenbeck@charite.de ∙ Prof Felix Bermpohl, MDa ∙ Karl Deutschera ∙ Prof Seena Fazel, MDb ∙ Prof Stefan Gutwinski, MDa,† ∙ Stefanie Schreiter, MD https://www.thelancet.com/journals/lanpub/article/PIIS2468-2667(26)00092-7/fulltext?dgcid=hubspot_update_feature_updatealerts_lanpub&utm_campaign=update-lanpub&utm_medium=email&_hsenc=p2ANqtz-_XN7WMtkmSw1fsErQt5NXOkS81Aw4Qd9qI0tH3JQN62LpDS_JE9BHENjZE5dvq8rUIXW6xuGpFoirYWjq1oUejWqz6gA&_hsmi=427330715&utm_content=427086455&utm_source=hs_email

Understanding sugar-sweetened beverage tax implementation globally: a 34-year, population-based observational study in 183 countries Lizbeth Moreno Loaeza, PhDa Send email to lizbeth.loaeza_moreno@tufts.edu ∙ Laura Lara-Castor, PhDa,b ∙ Julia R Sharib, MSa ∙ Frederick Cudhea, PhDa ∙ Meng Wang, PhDa ∙ Peizhi Li, PhDa,c ∙ et al.

Understanding sugar-sweetened beverage tax implementation globally: a 34-year, population-based observational study in 183 countries Lizbeth Moreno Loaeza, PhDa Send email to lizbeth.loaeza_moreno@tufts.edu ∙ Laura Lara-Castor, PhDa,b ∙ Julia R Sharib, MSa ∙ Frederick Cudhea, PhDa ∙ Meng Wang, PhDa ∙ Peizhi Li, PhDa,c ∙ et al. https://www.thelancet.com/journals/langlo/article/PIIS2214-109X(26)00093-8/fulltext?dgcid=hubspot_update_feature_updatealerts_langlo&utm_campaign=update-langlo&utm_medium=email&_hsenc=p2ANqtz-8sCux6eIjayecrmPzo0vyNNtNu-3ffdJosaoUkQO7AgAgSMQyQ4v9f3JrSpNDnOLwsEQqzpXkTl8W3qCdgV4SFroa1wg&_hsmi=427149859&utm_content=427079580&utm_source=hs_email

Inclusion of young adolescents in policy development for new tuberculosis vaccines Prof Mark Hatherill, MDa Send email to mark.hatherill@uct.ac.za ∙ Rebecca A Clark, PhDb ∙ Leonardo Martinez, PhDc ∙ Andrew L Fiore-Gartland, PhDd ∙ Prof Alberto L Garcia-Basteiro, PhDe,f,g ∙ Prof Gavin J Churchyard, PhDh,i,j ∙ et al.

Inclusion of young adolescents in policy development for new tuberculosis vaccines Prof Mark Hatherill, MDa Send email to mark.hatherill@uct.ac.za ∙ Rebecca A Clark, PhDb ∙ Leonardo Martinez, PhDc ∙ Andrew L Fiore-Gartland, PhDd ∙ Prof Alberto L Garcia-Basteiro, PhDe,f,g ∙ Prof Gavin J Churchyard, PhDh,i,j ∙ et al. https://www.thelancet.com/journals/langlo/article/PIIS2214-109X(26)00017-3/fulltext?dgcid=hubspot_update_feature_updatealerts_langlo&utm_campaign=update-langlo&utm_medium=email&_hsenc=p2ANqtz-99VZ22ynsx7Czu-IJDNLdOzMGqREKWS6kUFcDejSoYjY6yFYo4fkhhbGA74kNOpmueOysWpnymuZOxjAQSp7Bolxs2UA&_hsmi=427149859&utm_content=427079580&utm_source=hs_email Issue cover for Volume 14, Issue 6 Jun 2026 Volume 14Number 6 https://www.thelancet.com/journals/langlo/issue/vol14no6/PIIS2214-109X(26)X2004-6

Save the Date: Evidence Guided Psychiatric Medication De-Prescribing Support Thursday, July 16, 3–4:30 p.m. ET

https://zoom.us/webinar/register/WN_BPZj_7JgQhiHYv5UOAvKBQ?utm_source=SAMHSA&utm_campaign=5ebb7911be-EMAIL_CAMPAIGN_2026_07_06_02_34&utm_medium=email&utm_term=0_-5ebb7911be-167840245#/registration

Decoding the host–microbiome dialogue with biological foundation models eBioMedicine +...

Decoding the host–microbiome dialogue with biological foundation models eBioMedicine https://www.thelancet.com/journals/ebiom/issue/vol129nonull/PIIS2352-3964(26)X2005-9

Children and adolescents in the humanitarian response The Lancet Child & Adolescent Health +...

Children and adolescents in the humanitarian response The Lancet Child & Adolescent Health https://www.thelancet.com/journals/lanchi/issue/vol10no8/PIIS2352-4642(26)X2006-5

Precision Oncology in HER2-Mutated NSCLC: Strategies for Today and Tomorrow Authors: Yong Fang, MD; Hye Ryun Kim, MD, PhD; Hibiki Udagawa, MD, Ph

https://www.medscape.org/viewarticle/precision-oncology-her2-mutated-nsclc-strategies-today-and-2025a100105r?page=1&src=mkmcmr_driv_stan_mscpedu_260708-OUS-HONC-precision-oncology-her2-mutated-nsclc-strategies-today-and-2025a100105r-cta&uac=148436CN

Project Hail Mary: the universe without Einstein By Bioethics Observatory Published On: June 16th, 2026 Categories: Bioethics, BIOETHICS NEWS, ++++

https://bioethicsobservatory.org/2026/06/project-hail-mary-the-universe-without-einstein/48866/?utm_source=mailpoet&utm_medium=email&utm_source_platform=mailpoet Would we have been able to understand the universe today without Albert Einstein’s intuition? Inspired by a captivating science fiction premise—an alien civilization capable of interstellar travel yet entirely ignorant of relativity—this article explores Einstein’s singular contribution to the history of science. The Theory of General Relativity arose not from a mere accumulation of experimental data, but from a remarkable intellectual audacity driven by what the physicist himself considered a “moral responsibility toward the truth.” Without his courage to challenge classical concepts and discover that space and time form a dynamic fabric, our contemporary understanding of the cosmos, the origin of the Big Bang, and even everyday technologies like GPS would be impossible today. Human genetic enhancement reignites ethical debate in science By Bioethics Observatory Published On: June 2nd, 2026 Categories: Bioethics, BIOETHICS NEWS, https://bioethicsobservatory.org/2026/06/human-genetic-enhancement-reignites-ethical-debate-in-science/48838/?utm_source=mailpoet&utm_medium=email&utm_source_platform=mailpoet The possibility of genetically modifying human beings no longer belongs solely to the realm of science fiction. Rapid advances in gene-editing techniques such as CRISPR have generated intense scientific, ethical, and social debate about the limits of intervention in human nature, especially considering the development of applications aimed not only at curing diseases but also at enhancing physical and cognitive … New studies on Down syndrome reopen the bioethical debate on fetal research By Bioethics Observatory Published On: June 4th, 2026 Categories: Bioethics, BIOETHICS NEWS, https://bioethicsobservatory.org/2026/06/new-studies-on-down-syndrome-reopen-the-bioethical-debate-on-fetal-research/48846/?utm_source=mailpoet&utm_medium=email&utm_source_platform=mailpoet Two recent research papers published in Science and PNAS have reignited the debate on Down syndrome, gene editing, and the ethical limits of biomedical research. While one of the studies analyzed the molecular alterations in fetal brain development in fetuses with trisomy 21 obtained after induced abortions, the other explored silencing of the extra chromosome 21 found in this syndrome using CRISPR-Cas9 technology. Although both papers point to potential therapeutic advances, they also raise profound bioethical questions about the use of aborted fetuses in research, the dignity of human life, and the moral implications of intervening genetically in humans before birth. CRISPR goes one step further: the new technique that can kill diseased cells without editing DNA By Bioethics Observatory Published On: May 27th, 2026 Categories: Bioethics, BIOETHICS NEWS, https://bioethicsobservatory.org/2026/05/crispr-goes-one-step-further-the-new-technique-that-can-kill-diseased-cells-without-editing-dna/48810/?utm_source=mailpoet&utm_medium=email&utm_source_platform=mailpoet CRISPR gene editing has evolved over the past decade from an experimental tool to a therapeutic platform with clinical trials in multiple areas: hematology, oncology, and rare, infectious, and metabolic diseases. In 2025, over 65 clinical trials evaluated CRISPR technologies or base editors to treat human diseases. One of these led to the development of CasgevyTM—approved for the treatment of sickle cell anemia and beta-thalassemia—which involves ex vivo genetic modification of the patient’s own CD34+ hematopoietic stem cells using CRISPR-Cas9.[1] An in vivo gene therapy technique for hypercholesterolemia has also shown positive findings.[2]

Stochastic oscillations in neural models with static and dynamic Hopf bifurcation parameters Priscilla E. Greenwood [1] , Lawrence M. Ward* [2,3]

https://www.academia.edu/3071-4087/2/3/10.20935/AcadNeurosci8395 Here, we review how and when stochastic oscillations arise in stochastic dynamical model neural systems with supercritical Hopf bifurcations, and point to relevant mathematical results. We focus on four models of neural activity, all of which display supercritical Hopf bifurcations. To address neural plasticity we study two-time, slow–fast versions of these models in which the bifurcation parameter is slowly changing. We display with simulations the effect of noise on the dynamics of both base system (fixed bifurcation parameter) and slow–fast system (changing bifurcation parameter) models. Adding noise to a slow–fast model eliminates the bifurcation delay and induces what we term ‘noisy-delay-cycles’ during what would be the delay period in a deterministic solution. We measure both quasi-cycles, when the slow parameter is below the Hopf point, and noisy-delay-cycles during the delay period above the Hopf point. We also compute the power spectral density for each of the models, showing that all are versions of Lorentzians with peaks at the inflection points, representing the model-generated oscillations. We conclude that, given the similarities of the local dynamics of these models near the Hopf point under moderate noise, there is little reason to favour one model over another when studying the behaviour of large groups of neurons, i.e., when used as neural mass models, particularly as part of whole-brain network models. https://www.academia.edu/journals/academia-neuroscience-and-brain-research/articles?source=journal-top-nav

HER2-Positive Gastroesophageal Adenocarcinoma and Biliary Tract Cancer: Updates and Insights Authors: Haley Ellis, MD; Steven Maron, MD, MSc

https://www.medscape.org/viewarticle/her2-positive-gastroesophageal-adenocarcinoma-and-biliary-2025a1000sr3?page=1&src=mkmcmr_driv_stan_mscpedu_260706-OUS-HONC-her2-positive-gastroesophageal-adenocarcinoma-and-biliary-2025a1000sr3-cta&uac=148436CN

How Are ADCs Shaping the Future of Early Breast Cancer Care? Latest Insights and Emerging Strategies Authors: Nadia Harbeck, MD, PhD; Giuseppe Curigliano, MD, PhD

https://www.medscape.org/viewarticle/how-are-adcs-shaping-future-early-breast-cancer-care-latest-2025a1000yca?page=1&uac=148436CN&src=mkmcmr_driv_stan_mscpedu_260706-OUS-HONC-how-are-adcs-shaping-future-early-breast-cancer-care-latest-2025a1000yca-cta

FDA Alerts Health Care Providers to Cases of Neurologic Complications from General Anesthesia Linked to Genetic Variant in Patients of Maternal Venezuelan Ancestry

https://content.govdelivery.com/accounts/USFDA/bulletins/41f3fb0?reqfrom=share The U.S. Food and Drug Administration (FDA) is investigating the safety of sevoflurane and other general anesthetics based on published scientific reports of unexpected catastrophic outcomes, including severe neurologic adverse outcomes and death, occurring in adult and pediatric patients of maternal Venezuelan ancestry following routine general anesthesia with sevoflurane. In light of the recent earthquakes in Venezuela, FDA wants to ensure that agencies or groups providing medical resources to Venezuelans and health care providers traveling to the country are aware of these rare but serious events. A rare mitochondrial genetic variant (MT-ND4 m.11232T>C) has been reported in a subset of patients who experienced serious adverse events following exposure to sevoflurane. Although the currently reported cases have been linked to sevoflurane, this genetic variant raises concerns regarding all volatile anesthetics. FDA is continuing to review this emerging safety concern for implications for the U.S. population and FDA-approved anesthetic products. Until more information is available, agencies or groups providing medical resources to Venezuelans and health care providers working in Venezuela may consider using alternatives to volatile anesthetics, such as intravenous anesthetics or regional anesthesia, where clinically appropriate and available. Health care providers and patients are encouraged to report adverse events or side effects related to the use of these products to the FDA's MedWatch Safety Information and Adverse Event Reporting Program:

Do metals in tampons pose a health risk? A toxicological risk assessment study Get access Arrow Ying Jin , Michael Eppihimer , Md Shah Alam , Anne T Powell , Edward Margerrison , Arghavan Victoria Nawaby

https://academic.oup.com/toxsci/article-abstract/209/6/kfag065/8698879?redirectedFrom=fulltext&login=true&utm_source=govdelivery&utm_medium=email

Menstrual Product Options, Facts, and Safe Use

https://www.fda.gov/medical-devices/products-and-medical-procedures/menstrual-product-options-facts-and-safe-use?utm_medium=email&utm_source=govdelivery

Coping With Grief | Wildfire Safety | Early-Life Metal Exposure | High Blood Pressure Support | NIH Health Information

https://newsinhealth.nih.gov/

Beyond the Update in Advanced/Recurrent Endometrial Cancer: How Evidence Is Shaping New Guidelines Authors: Nicole Concin, MD, PhD; Els Van Nieuwenhuysen, MD, PhD; Xavier Matias-Guiu, MD, PhD

https://www.medscape.org/viewarticle/beyond-update-advanced-recurrent-endometrial-cancer-how-2026a10006up?page=1&src=mkmcmr_driv_stan_mscpedu_260706-OUS-HONC-beyond-update-advanced-recurrent-endometrial-cancer-how-2026a10006up-cta&uac=148436CN

Amylin: A Novel Diabetes and Obesity Therapy

https://www.medscape.com/viewarticle/amylin-novel-diabetes-and-obesity-therapy-2026a1000lvm?ecd=WNL_trdalrt_pos1_ous_260707_etid8484935&uac=148436CN&impID=8484935 For several years now, SGLT2 inhibitors and incretin therapies have dominated the diabetes therapeutic landscape because of their glucose-lowering potency, low associated risk for hypoglycemia, weight-loss properties, and other cardio-renal-metabolic benefits. Incretin therapies are also well established as an obesity treatment in patients without diabetes.

IMPACT EBC: IMPlementing Advances in Cancer Treatment for Patients With HR+/HER2- Early Breast Cancer - Moving Patient Care Forward

https://www.medscape.org/advances/implementing-advances-cancer-treatment-patients-hr-her2-2025a1000yzz?src=ban_driv_260303_mscpedu_447301.01_ace

Q&A: Managing GI Toxicities of Immunotherapy Liam Davenport July 07, 2026

https://www.medscape.com/viewarticle/q-managing-gi-toxicities-immunotherapy-2026a1000mwi

Dignity Therapy: What Matters Most in End-of-Life Care? Irene Salvetti, MD,

https://www.medscape.com/viewarticle/dignity-therapy-what-matters-most-end-life-care-2026a1000mak?src=

Cooling the Flame: Evidence-Based Management of Vasomotor Symptoms in Breast Cancer Michelle E. Melisko, MD

https://www.medscape.com/viewarticle/cooling-flame-evidence-based-management-vasomotor-symptoms-2026a1000lon?src=

Beyond Weight Loss: The Expanding Role of GLP-1s in Oncology Coral Olazagasti, MD; Carolina Bernabe, MD

https://www.medscape.com/viewarticle/beyond-weight-loss-expanding-role-glp-1s-oncology-2026a1000lo3?src=

Extreme Heat: Is Health Toll Worse Than We Think? Roberta Villa Medscape Europe logo July 07, 2026

https://www.medscape.com/viewarticle/extreme-heat-health-toll-worse-than-we-think-2026a1000mol It's hot, and no, it should not be taken for granted that we have to endure temperatures like those we have been experiencing over the past few days, already at the beginning of summer (in fact, as I write this, astronomically speaking, it's still spring). It has not always been this hot, with temperatures this high for so many consecutive days and no relief even at night. This affects everyone's health, not just that of the most vulnerable. With the population of Europe continuing to age with an increase in extreme weather events, the consequences can only become more severe.

Informed, empowered, and engaged: fertility care for the modern era The Lancet Obstetrics, Gynaecology, & Women's Health +...

Informed, empowered, and engaged: fertility care for the modern era The Lancet Obstetrics, Gynaecology, & Women's Health https://www.thelancet.com/journals/lanogw/issue/vol2no7/PIIS3050-5038(26)X2006-4

A new blueprint for the rational design of siRNA drugs Written byAllison Whitten, PhD

A new blueprint for the rational design of siRNA drugs For the first time, researchers imaged a human protein essential to the RNA interference process and found ways to design better siRNA drugs. Written byAllison Whitten, PhD https://www.drugdiscoverynews.com/a-new-blueprint-for-the-rational-design-of-sirna-drugs-17296

Aligning regulation and manufacturing for the next wave of small molecules Written byBree Foster, PhD

Aligning regulation and manufacturing for the next wave of small molecules The Synthetic Molecule Process Innovation Phorum brings together major pharma companies, regulators, and CDMOs to build consensus on pressing challenges in small molecule manufacturing. Written byBree Foster, PhD https://www.drugdiscoverynews.com/aligning-regulation-and-manufacturing-for-the-next-wave-of-small-molecules-17297

Advancing Personalized Care for Prostate Cancer: Patient-Centered Solutions for mHSPC and nmCRPC Authors: Alicia K. Morgans, MD, MPH, FASCO; Christian Gratzke, MD; Fred Saad, MD, FRCS, FCAHS; Tony Collier, BEM

https://www.medscape.org/viewarticle/advancing-personalized-care-prostate-cancer-patient-centered-2025a1000uyb?page=1&src=mkmcmr_driv_stan_mscpedu_260707-OUS-HONC-advancing-personalized-care-prostate-cancer-patient-centered-2025a1000uyb-cta&uac=148436CN

A Phase 3 Study with Atacicept in Subjects With IgA Nephropathy (ORIGIN 3)

https://clinicaltrials.gov/study/NCT04716231?id=NCT04716231&rank=1&utm_medium=email&utm_source=govdelivery&viewType=Card Notable Approval: FDA Approves New Treatment to Reduce Proteinuria in Adults with Primary Immunoglobulin A Nephropathy The U.S. Food and Drug Administration (FDA) has approved Trutakna (atacicept-vymj) to reduce proteinuria in adults with primary immunoglobulin A nephropathy at risk for disease progression. Trutakna is injected subcutaneously (under the skin) once weekly. Condition IgA nephropathy is a serious kidney disease that occurs when an abnormal form of an immunoglobulin A (IgA) antibody builds up in the kidneys, causing kidney inflammation and damage. This kidney damage can cause protein to leak from the blood into the urine (proteinuria) and loss of kidney function over time that may progress to kidney failure. Data Supporting Trutakna Trutakna is the first FDA-approved medicine that targets both B cell activating factor (BAFF) and A Proliferation Inducing Ligand (APRIL), which are involved in survival and maturation of certain immune cells. This in turn decreases production of the abnormal IgA antibody. The efficacy and safety of Trutakna were evaluated in a randomized, double-blind, placebo-controlled clinical trial (NCT04716231) in adults with biopsy-confirmed IgA nephropathy. Patients were randomly assigned to either Trutakna 150 mg injected subcutaneously once weekly or placebo. The primary efficacy endpoint assessed the change from baseline in proteinuria (urine protein-to-creatinine ratio sampled from a 24-hour urine collection) after 9 months of treatment in the first 203 patients who had the opportunity to reach the month 9 visit. At 9 months, patients in the Trutakna group had an average 46% reduction in proteinuria as compared to an proteinuria in the placebo group. Safety Information Trutakna suppresses the immune system and may increase the risk of infections. Patients should be assessed for active infections before starting Trutakna and monitored for signs of infection during treatment. Trutakna may interfere with the immune response to vaccines and increase the risk of infection from live vaccines. Administration of live vaccines is not recommended within 30 days prior to starting Trutakna or during treatment with Trutakna. The most common side effects of Trutakna are infections (including upper respiratory tract infection) and injection site reactions, including injection site erythema (redness of the skin). Designations Trutakna was granted accelerated approval based on the reduction in proteinuria. It has not been established whether Trutakna slows kidney function decline over the long-term in patients with IgA nephropathy. As a condition of the accelerated approval, the ongoing clinical trial must be completed to confirm that Trutakna slows kidney function decline over the long-term in patients with IgA nephropathy. Continued approval may be contingent upon verification of clinical benefit in this confirmatory trial. The approval was granted to Vera Therapeutics, Inc. Trutakna also received priority review and Breakthrough Therapy designation for this indication.

WHIM Syndrome Full Panel Discussion (9 videos)

Mental Health Challenges and Care Gaps in Patients With Lipodystrophy

A Patient’s Diagnostic Journey With Congenital Adrenal Hyperplasia

Results from the CALIBRATE Clinical Trial in Patients With Autosomal Dominant Hypocalcemia Type 1

Congenital Hyperinsulinism Diagnosis and Management

Treatment With Xywav (Low Sodium Oxybate) in Patients With Narcolepsy and Idiopathic Hypersomnia by Madaline Spencer| Published on: Jul 6, 2026

Treatment With Xywav (Low Sodium Oxybate) in Patients With Narcolepsy and Idiopathic Hypersomnia by Madaline Spencer| Published on: Jul 6, 2026 Logan Schneider, MD, Adjunct Clinical Associate Professor of Psychiatry and Behavioral Sciences at Stanford University, discusses treatment with Xywav (low sodium oxybate) in patients with sleep disorders, narcolepsy and idiopathic hypersomnia. https://checkrare.com/treatment-with-xywav-low-sodium-oxybate-in-patients-with-narcolepsy-and-idiopathic-hypersomnia/

Lung Cancer Stigma Can Kill By Ivanhoe Broadcast News on July 10, 2026

ORLANDO, Fla. (Ivanhoe Newswire) — Lung cancer kills more people every year than colon, breast, and prostate cancer combined, accounting for one in five of all cancer deaths. And yet, because most cases are caused by smoking, there’s a stigma that if you get lung cancer, you deserve it. Ivanhoe tells us how this stigma hurts patients from diagnosis to treatment. https://www.ivanhoe.com/?p=37287&preview=1&_ppp=da761bbb56

The Gift of Sound: Hearing Clinic on Wheels By Ivanhoe Broadcast News on July 9, 2026

RALEIGH, NC. (Ivanhoe Newswire) — In the United States, as many as three out of every thousand babies are born with some degree of hearing loss — making it one of the most common conditions identified in newborns. But for many families, especially those in rural communities, access to specialists and early care can be a major barrier. One that significantly decreases their chances of developing speech and language. https://www.ivanhoe.com/?p=37284&preview=1&_ppp=f95a6057a7

Pregnant And Spinning Out: Perinatal Psychosis By Ivanhoe Broadcast News on July 8, 2026

ORLANDO, Fla. (Ivanhoe Newswire) — When you think about mental health conditions related to pregnancy, you probably think, for example, postpartum depression begins after birth. But some conditions can start even before a bump appears! Classified as perinatal mood and anxiety disorders, these conditions can occur from conception up to a year after birth. https://www.ivanhoe.com/?p=37281&preview=1&_ppp=16989a5a82

Anemia: Identifying It and Finding Bigger Problems By Ivanhoe Broadcast News on July 7, 2026

ORLANDO, FLA. (Ivanhoe Newswire) — At its base, anemia occurs when your red blood cell count is low. But the condition gets a lot more complicated from there. If doctors think they have found anemia, they have to ask themselves: What’s the cause? What’s the size of the red blood cells? Is it genetic? But it could still take time to get a diagnosis as some anemias are sneaky and disguise themselves as other problems. https://www.ivanhoe.com/?p=37278&preview=1&_ppp=5da181b385

Help From Above: AEDS Delivered by Drones By Ivanhoe Broadcast News on July 6, 2026

RALEIGH, NC. (Ivanhoe Newswire) — Every year in the United States more than 350 thousand people suffer cardiac arrest and fewer than 10 percent survive. One of the biggest reasons — time. When a heart stops, every minute without treatment reduces survival by about 10 percent. And despite decades of medical advances that survival rate has changed very little. Now, researchers are testing a first-of-its kind, high-tech way to close that critical gap. AED https://www.ivanhoe.com/family-health/help-from-above-aeds-delivered-by-drones/

Navigating Myelofibrosis-Associated Anemia Together: Empowering Collaboration and Communication Authors: Francesco Passamonti, MD

https://www.medscape.org/viewarticle/navigating-myelofibrosis-associated-anemia-together-2026a10007ks?page=1&src=mkmcmr_driv_stan_mscpedu_260706-OUS-HONC-navigating-myelofibrosis-associated-anemia-together-2026a10007ks-cta&uac=148436CN

Advancing Clinical Excellence IMPACT CLL & MCL: IMPlementing Advances in Cancer Treatment for Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma ++++++

https://www.medscape.org/advances/impact-cll-mcl-2025a1000ar6?src=mkmcmr_driv_32025_mscpedu_421115.01_ace_final&uac=148436CN Explore Available CME Activities Relapsed/Refractory CLL: Can You Apply Recent Evidence and Guidelines to These Challenging Cases? https://www.medscape.org/viewarticle/relapsed-refractory-cll-can-you-apply-recent-evidence-and-2025a1000bg4?page=1&src=mkmcmr_driv_32025_mscpedu_421115.01_ace_final&uac=148436CN 1.25 CME / ABIM MOC 75 Min View Activity Activity 1 Image Collaborative Care: Navigating Multidisciplinary Management of CLL and MCL for Optimal Patient Outcomes https://www.medscape.org/viewarticle/1002602?src=mkmcmr_driv_32025_mscpedu_421115.01_ace_final&uac=148436CN CME / ABIM MOC / CE 1.00 View Activity Activity 2 Image Patient Insights Illuminated: A Rapid-Fire Dive Into CLL and MCL https://www.medscape.org/viewarticle/1002737?src=mkmcmr_driv_32025_mscpedu_421115.01_ace_final&uac=148436CN 0.75 CME / ABIM MOC / CE View Activity Activity 3 Image Virtual Patient Simulation for CLL: Test Your Skills https://www.medscape.org/viewarticle/virtual-patient-simulation-cll-test-your-skills-2025a1000wjp?page=1&src=mkmcmr_driv_32025_mscpedu_421115.01_ace_final&uac=148436CN 1.0 CME/MOC View Activity Activity 4 Image Mastering Oral Therapies in CLL/SLL and MCL: Essential Strategies and Insights for Nurses https://www.medscape.org/viewarticle/mastering-oral-therapies-cll-and-mcl-essential-strategies-2025a1000xko?page=1&src=mkmcmr_driv_32025_mscpedu_421115.01_ace_final&uac=148436CN 1 .0 CME/CE View Activity

Venetoclax-Obinutuzumab Boosts MRD Clearance in CLL Edited by Gargi Mukherjee July 06, 2026 Blood. 2026;147(24):2895-2904. doi:10.1182/blood.2025030630

https://www.medscape.com/viewarticle/venetoclax-obinutuzumab-boosts-mrd-clearance-cll-2026a1000mqf?src= In fit patients with untreated chronic lymphocytic leukemia (CLL), first-line treatment with fixed-duration venetoclax-obinutuzumab was associated with higher undetectable minimal residual disease (MRD) rates than fludarabine, cyclophosphamide, and rituximab/bendamustine-rituximab in the phase 3 CRISTALLO trial.

Can Elevated MMP12 Levels Predict Risk for Pancreatic Cancer Years Before Diagnosis? Edited by Vineeta Teotia

https://www.medscape.com/viewarticle/can-elevated-mmp12-levels-predict-risk-pancreatic-cancer-2026a1000mk2?src= In a case-control study, higher levels of the immune protein MMP12 were associated with an increased risk for pancreatic cancer, particularly among individuals diagnosed within 8 years of blood collection, with the strongest associations observed in those diagnosed within 4 years.

Navigating Cytopenias in Myelofibrosis: Tailoring Personalized Care for Optimal Outcomes Authors: Francesca Palandri, MD; Vikas Gupta, MD, FRCPath; Jennifer O'Sullivan, MD

https://www.medscape.org/viewarticle/navigating-cytopenias-myelofibrosis-tailoring-personalized-2026a10004km?page=1&src=mkmcmr_driv_stan_mscpedu_260705-OUS-HONC-navigating-cytopenias-myelofibrosis-tailoring-personalized-2026a10004km-cta&uac=148436CN

Equal stakeholders: how FESCA is preparing patient advocates to reshape scleroderma research 6 July 2026

https://rarerevolutionmagazine.com/equal-stakeholders-how-fesca-is-preparing-patient-advocates-to-reshape-scleroderma-research/ The Federation of European Scleroderma Associations (FESCA) is working to move patient involvement in research from token gesture to genuine partnership. Sue Farrington, president, FESCA and chief executive of Scleroderma and Raynaud’s UK (SRUK), and Ilaria Galetti, vice president of FESCA, share how training, language and structural shifts can turn a patient voice into research that reflects their greatest needs Written by Nicola Miller, RARE Revolution Interview with Sue Farrington, president FESCA, chief executive, Scleroderma and Raynaud’s UK (SRUK) and, and Ilaria Galetti, vice president, FESCA

Beyond the platelet count. The lifelong burden of immune thrombocytopenia 1 July 2026

https://rarerevolutionmagazine.com/beyond-the-platelet-count-the-lifelong-burden-of-immune-thrombocytopenia/ Immune thrombocytopenia (ITP) is widely understood as a bleeding disorder defined by low platelets. For the people who live with it, that definition is incomplete. Fatigue, cognitive symptoms, anxiety and the slow erosion of working and family life are often the heavier burdens, and none of them can be read from a blood test. Barbara Lovrencic, president of the Italian ITP patient association AIPIT, explains why care that looks past the count is long overdue

From collapse to new kneecaps: a dystonia journey 1 July 2026

https://rarerevolutionmagazine.com/from-collapse-to-new-kneecaps-a-dystonia-journey/ Almost four years on from her dystonia diagnosis, Becky Johnson reflects on what her life has been like. From the frequent collapsing episodes to the technology that helped her manage her condition and the medical treatment and procedures she has undergone By Becky Johnson Stumbling upon a collection of private video journals I recorded during the first six months after my dystonia diagnosis in August 2022 was unexpected. Scattered alongside a few other clips from the last four years, they had entirely slipped my mind. Rewatching those early entries proved to be both a heavy emotional burden and a profound gift. One video vividly captured a collapsing episode—just one of many I endured last summer. During these collapsing episodes, a sensation would steadily drain from my legs until they refused to work altogether. I would sink to the ground in slow motion. Usually, with a helping hand, I would make it to bed and fall into a deep sleep for a few hours. Upon waking, my mobility typically returned, though I vividly recall moments where my legs felt weak, detached and entirely foreign to how normal human limbs should operate.

Beyond the surface: the invisible impact of myasthenia gravis 1 July 2026

https://rarerevolutionmagazine.com/beyond-the-surface-the-invisible-impact-of-myasthenia-gravis/ Myasthenia gravis (MG) is a rare, autoimmune condition that can quietly reshape lives. For Alisa, those changes began to develop early in her adulthood. Aged 21, her life changed in a matter of weeks. Before, her life was social, filled with creativity and movement, but since developing MG, that all changed. Alisa is a graphic designer and illustrator from Bucharest, Romania. Dr Channa Hewamadduma is a consultant neurologist based in Sheffield, England. Here, they come together to talk openly about what it really means to live with and care for people living with this unpredictable, often invisible condition

Making neurology care transitions work for young patients The Lancet Neurology +... // Glimmers of hope in times of war The Lancet Psychiatry +...

Making neurology care transitions work for young patients The Lancet Neurology https://www.thelancet.com/journals/laneur/issue/vol25no7/PIIS1474-4422(26)X2005-1 Glimmers of hope in times of war The Lancet Psychiatry https://www.thelancet.com/journals/lanpsy/issue/vol13no7/PIIS2215-0366(26)X2005-3

Editorial Stroke still strikes hard: we need more primary prevention The Lancet Regional Health – Americas +...

Editorial Stroke still strikes hard: we need more primary prevention The Lancet Regional Health – Americas https://www.thelancet.com/journals/lanam/issue/vol58nonull/PIIS2667-193X(26)X2003-8

Editorial No escape: crisis of extreme heat indoors The Lancet Regional Health – South East Asia +...

Editorial No escape: crisis of extreme heat indoors The Lancet Regional Health – South East Asia https://www.thelancet.com/journals/lansea/issue/vol49nonull/PIIS2772-3682(26)X2004-2

Trust in science How to build and maintain public support in an era of polarization A Nature special 1 July 2026

https://www.nature.com/immersive/d42859-026-00025-w/index.html?utm_source=Live+Audience&utm_campaign=840588bfc4-nature-briefing-daily-20260703&utm_medium=email&utm_term=0_-33f35e09ea-50432164

Highlights From the Annual Neuro-Oncology Conference: Redefining IDH-Mutant Glioma Management Authors: Evanthia Galanis, MD; Shawn Hervey-Jumper, MD; Katherine B. Peters, MD, PhD, FAAN; Matthias Preusser, MD

https://www.medscape.org/viewarticle/1003198?src=mkmcmr_driv_stan_mscpedu_260704-OUS-HONC-1003198-cta&uac=148436CN

Mastering Oral Therapies in CLL and MCL: Essential Strategies and Insights for Nurses Authors: Amy L. Goodrich, RN, MSN, CRNP-AC; Claudia Boglione, RN; Natacha Bolanos

https://www.medscape.org/viewarticle/mastering-oral-therapies-cll-and-mcl-essential-strategies-2025a1000xko?page=1&uac=148436CN&src=mkmcmr_driv_stan_mscpedu_260704-OUS-HONC-mastering-oral-therapies-cll-and-mcl-essential-strategies-2025a1000xko-cta

Chronic Lymphocytic Leukemia (CLL): Review of Combination Approaches Authors: Jonathon Cohen, MD, MS; Matthew S. Davids, MD, MMSc

https://www.medscape.org/viewarticle/chronic-lymphocytic-leukemia-cll-review-combination-2026a10004ku?page=1&src=mkmcmr_driv_stan_mscpedu_260705-OUS-HONC-chronic-lymphocytic-leukemia-cll-review-combination-2026a10004ku-cta&uac=148436CN

Abrupt discontinuation and tapering of antipsychotics in older adults with dementia: a target trial emulation study Olivia K Hopkinson, MSca ∙ Jan Chobanov, MSca ∙ Darshna Goordeen, GradDip[ClinPharm]b ∙ Kenneth K C Man, PhDa,c,d,e ∙ Prof Ian C K Wong, PhDa,c,d,e,f ∙ Emily Reeve, PhD

Abrupt discontinuation and tapering of antipsychotics in older adults with dementia: a target trial emulation study Olivia K Hopkinson, MSca ∙ Jan Chobanov, MSca ∙ Darshna Goordeen, GradDip[ClinPharm]b ∙ Kenneth K C Man, PhDa,c,d,e ∙ Prof Ian C K Wong, PhDa,c,d,e,f ∙ Emily Reeve, PhD https://www.thelancet.com/journals/lanhl/article/PIIS2666-7568(26)00036-X/fulltext?dgcid=hubspot_update_feature_updatealerts_lanhl&utm_campaign=update-lanhl&utm_medium=email&_hsenc=p2ANqtz--WhAA4PRnTM4nYtKANJVWBS1s1-oSxsGcNAunqBmBUiXobBoB8-hejqb009mBLN8m1XdmtKrAmeUHGSVmiE8O6PjDdQw&_hsmi=425952808&utm_content=425727608&utm_source=hs_email Antipsychotic use in people living with dementia has been linked to serious adverse outcomes. Guidelines recommend limiting antipsychotic treatment to short-term use (<12 weeks), followed by tapering and cessation. However, antipsychotic treatment in routine practice often exceeds the recommended duration. The effect of discontinuing antipsychotics on reducing adverse outcomes in practice remains unclear. We aimed to use linked primary and secondary care data in England to investigate whether tapering or abrupt discontinuation of antipsychotics, versus continuation, affected the risk of stroke, death, fracture, delirium, and pneumonia in people living with dementia.

The effects of anti-osteoporotic medication on fracture healing and outcomes: a systematic review and meta-analysis Nikhil Agarwal, MBChBa ∙ Katrina R Bell, MBChBa ∙ Lauren E Ross, MBChBa ∙ Nick D Clement, PhDa ∙ Prof Stuart H Ralston, MDb ∙ Prof Andrew D Duckworth, PhD

The effects of anti-osteoporotic medication on fracture healing and outcomes: a systematic review and meta-analysis Nikhil Agarwal, MBChBa ∙ Katrina R Bell, MBChBa ∙ Lauren E Ross, MBChBa ∙ Nick D Clement, PhDa ∙ Prof Stuart H Ralston, MDb ∙ Prof Andrew D Duckworth, PhD https://www.thelancet.com/journals/lanhl/article/PIIS2666-7568(26)00011-5/fulltext?dgcid=hubspot_update_feature_updatealerts_lanhl&utm_campaign=update-lanhl&utm_medium=email&_hsenc=p2ANqtz--QT3D7JjMNJNvQnfeKvPcFRQYj8hJhWWq9C6gEi2px483V12cDEJ1HeUaayjE4GfdU28vl_Wv_LCLOI_Yscr-biNWiNw&_hsmi=425952808&utm_content=425727608&utm_source=hs_email Bisphosphonates and teriparatide are used in the management of osteoporosis and reduction of fracture risk. However, their effects on fracture healing have been subject to debate, with concerns that the antiresorptive action of these drugs might impair bone remodelling and delay union. This systematic review and meta-analysis aimed to assess the effects of anti-osteoporotic medication on fracture union, clinical outcomes, complications, and patient-reported outcome measures for acute fractures in adults.

Stroke in older adults: exploring the intersections of comorbidity, disability, and frailty Terence J Quinn, Profa Send email to terry.quinn@glasgow.ac.uk ∙ Nicholas Evans, PhDc ∙ Patricia Fearon, MBChBd ∙ Katie I Gallacher, PhD

Stroke in older adults: exploring the intersections of comorbidity, disability, and frailty Terence J Quinn, Profa Send email to terry.quinn@glasgow.ac.uk ∙ Nicholas Evans, PhDc ∙ Patricia Fearon, MBChBd ∙ Katie I Gallacher, PhD https://www.thelancet.com/journals/lanhl/article/PIIS2666-7568(26)00037-1/fulltext?dgcid=hubspot_update_feature_updatealerts_lanhl&utm_campaign=update-lanhl&utm_medium=email&_hsenc=p2ANqtz-9qF7kRZTyWRc9oR1ZkXHYzlySaf6uVBBidLVXx9VFMteBLPoLULdpV0Vr74j2GPKiM81eiyPxvH77dSLb4kuzEBQQtJw&_hsmi=425952808&utm_content=425727608&utm_source=hs_email Although the epidemiology of cerebrovascular disease is changing, stroke remains predominantly a disease of older adults. Clinicians, researchers, and policy makers should, therefore, be familiar with the key contextual factors of older age and how these factors might affect stroke care. Arguably, the three overarching manifestations of complexity in ageing are: comorbidity, disability, and frailty. These conditions are all common in stroke and, alone or in combination, have important consequences for stroke care and outcomes. In a bidirectional relationship, each factor can also have modifying effects on stroke and the response to interventions. In this Review, we consider each of these factors in turn, providing a definition, guide to assessment, and implications for stroke care. We also describe the consequences of ageing across the entire stroke journey, from prevention through acute care to life after stroke. At each stage we offer examples of novel approaches or innovations in stroke care for older adults. Even though comorbidity, disability, and frailty are distinct, we observed common themes, namely that current stroke pathways do not adequately assess for these conditions and that the stroke community can learn from research in other aspects of older adult care.

Obesity drug mazdutide reduces weight and waist size in major trial

https://www.news-medical.net/news/20260609/Obesity-drug-mazdutide-reduces-weight-and-waist-size-in-major-trial.aspx?utm_source=news_medical_newsletter&utm_medium=email&utm_campaign=cardiology_newsletter_23_june_2026 A phase 3 trial shows that the dual GLP-1 and glucagon receptor agonist mazdutide drove substantial weight loss and cardiometabolic benefits, while highlighting gastrointestinal side effects that clinicians will need to manage. In a recent JAMA study, researchers reported the outcomes of the Phase 3 GLORY-2 clinical trial. The trial investigated the efficacy of mazdutide (the synthetic peptide analog of the natural mammalian peptide oxyntomodulin) in a cohort of Chinese adults with obesity (BMI ≥ 30 kg/m²) between December 2023 and November 2025.

GLP-1 medicines may cut clot-related risks in chronically inflamed patients

https://www.news-medical.net/news/20260610/GLP-1-medicines-may-cut-clot-related-risks-in-chronically-inflamed-patients.aspx?utm_source=news_medical_newsletter&utm_medium=email&utm_campaign=cardiology_newsletter_23_june_2026 A large real-world analysis suggests GLP-1 receptor agonists may offer clot-related and survival benefits in a chronically inflamed, high-risk population, while leaving some cardiovascular endpoints unchanged. In a recent study published in the Journal of the American Heart Association, researchers emulated a target trial to assess the association between glucagon-like peptide-1 receptor agonist (GLP-1RA) treatment and the risk of thromboembolic and cardiovascular events in adults with obesity and comorbid autoimmune disease (AID).

Apitegromab helps tirzepatide users lose fat while preserving lean mass

https://www.news-medical.net/news/20260609/Apitegromab-helps-tirzepatide-users-lose-fat-while-preserving-lean-mass.aspx?utm_source=news_medical_newsletter&utm_medium=email&utm_campaign=cardiology_newsletter_23_june_2026 A phase 2 trial suggests that blocking myostatin activation may help people taking tirzepatide retain more lean body mass without blunting weight loss. A recent phase II randomized clinical trial (RCT) published in the journal Nature Medicine showed that apitegromab, a monoclonal antibody, when administered along with tirzepatide, could help preserve lean body mass while supporting overall weight loss.

Oral GLP-1 drug elecoglipron helps adults lose up to 11.8% body weight

https://www.news-medical.net/news/20260611/Oral-GLP-1-drug-elecoglipron-helps-adults-lose-up-to-11825-body-weight.aspx?utm_source=news_medical_newsletter&utm_medium=email&utm_campaign=cardiology_newsletter_23_june_2026 A once-daily oral small-molecule GLP-1 receptor agonist delivered progressive, dose-dependent weight loss without food or fluid restrictions, supporting larger phase 3 trials for long-term weight management. In a recent study published in The Lancet, a group of researchers evaluated the efficacy, safety, and tolerability of oral non-peptide small-molecule elecoglipron for weight management in adults with obesity or overweight and at least one weight-related health condition without diabetes.

Statins may trigger muscle side effects by activating inflammatory danger signals

https://www.news-medical.net/news/20260622/Statins-may-trigger-muscle-side-effects-by-activating-inflammatory-danger-signals.aspx?utm_source=news_medical_newsletter&utm_medium=email&utm_campaign=cardiology_newsletter_23_june_2026 New experimental findings reveal how statins may push vulnerable muscle cells into a stress state, suggesting future strategies to reduce muscle symptoms without compromising cardiovascular protection. A recent study published in the journal Science Advances uncovered biological mechanisms that drive muscle-related side effects following statin therapy. The researchers found that statins reduced isoprenoid production, protein prenylation, and yes-associated protein (YAP) signaling.

New breast cancer classification system predicts immunotherapy response success

https://www.news-medical.net/news/20260703/New-breast-cancer-classification-system-predicts-immunotherapy-response-success.aspx The advent of immune checkpoint inhibitors (ICIs) has marked a paradigm shift in cancer treatment, yet a significant portion of breast cancer patients fail to respond to these therapies. The cancer-immunity cycle (CIC) is a conceptual framework that maps the step-by-step process of the anti-tumor immune response, from the release of cancer cell antigens to the killing of tumor cells by T cells. A defect in any single step can halt the entire cycle and render immunotherapy ineffective. However, most research has focused on individual steps, which fails to capture the complexity of the immune response. Due to these limitations, a more holistic and systematic approach is urgently needed to accurately assess a patient's immune status and guide treatment decisions.

Communicating to Enhance Care Through Data and Patient Experience: ER-Positive/HER2-Negative Metastatic Breast Cancer Edition Authors: Kelly Shanahan, MD; Sara Tolaney, MD, MPH; Virginia Kaklamani, MD, DSc; Sarah R. Donahue, MPH, NP, AOCNP; Abigail Shockley, PharmD, BCOP

https://www.medscape.org/viewarticle/communicating-enhance-care-through-data-and-patient-2025a1000uqi?page=1&uac=148436CN&src=mkmcmr_driv_stan_mscpedu_260629-OUS-HONC-communicating-enhance-care-through-data-and-patient-2025a1000uqi-cta

The new presidential fitness test is a positive step, not the solution, experts say The test risks embarrassing kids, turning them off from physical activity

https://www.statnews.com/2026/07/02/presidential-fitness-test-will-it-boost-physical-activity-youth/ By Chelsea CirruzzoJuly 2, 2026 Washington Correspondent

Teens are turning to chatbots for mental health help. We need rules to keep them safe Blanket bans may be tempting, but they aren’t the right fix

https://www.statnews.com/2026/07/02/teens-chatbots-mental-health-rules-bans/ By Ryan McBainJuly 2, 2026 McBain is an assistant professor at Harvard Medical School and a senior policy researcher at RAND.

How partnership accelerated access to innovative bladder cancer treatment at a community urology practice

https://www.statnews.com/sponsor/2026/05/26/how-partnership-accelerated-access-to-innovative-bladder-cancer-treatment-at-a-community-urology-practice/

Pediatric Cancer in the 2000s: Uneven Survival Gains Seen Richard Mark Kirkner Cancer. 2026;132(13):e70505. doi:10.1002/cncr.70505

https://www.medscape.com/viewarticle/pediatric-cancer-2000s-uneven-survival-gains-seen-2026a1000mmc?src= Over the previous two decades, overall survival for children with cancer has improved unevenly. Survival gains varied by cancer, and the demographic factors of race and ethnicity, economic status, and zip code also seemed to be driving disparities in cancer survival, according to a large population analysis of a national database.

HER2-Mutated NSCLC: Are Your Clinical Decisions on Target? Authors: Nicolas Girard, MD, PhD

https://www.medscape.org/viewarticle/her2-mutated-nsclc-are-your-clinical-decisions-target-2026a10000gu?page=1&src=mkmcmr_driv_stan_mscpedu_260704-OUS-HONC-her2-mutated-nsclc-are-your-clinical-decisions-target-2026a10000gu-cta&uac=148436CN

Results From the VISIONARY Clinical Trial of Sibeprenlimab in Patients With IgA Nephropathy by Madaline Spencer| Published on: Jun 29, 2026

Results From the VISIONARY Clinical Trial of Sibeprenlimab in Patients With IgA Nephropathy by Madaline Spencer| Published on: Jun 29, 2026 Vlado Perkovic, MD, Professor of Medicine and Provost at the University of New South Wales Sydney, discusses results from the VISIONARY clinical trial testing Voyxact (sibeprenlimab) in patients with IgA nephropathy (IgAN). https://checkrare.com/results-from-the-visionary-clinical-trial-of-sibeprenlimab-in-patients-with-iga-nephropathy/

FDA Grants Full Approval to Afami-Cel for Patients With Synovial Sarcoma by Madaline Spencer| Published on: Jun 30, 2026

https://checkrare.com/fda-grants-full-approval-to-afami-cel-for-patients-with-synovial-sarcoma/ The US Food and Drug Administration (FDA) has granted full approval to Tecelra (afamitresgene autoleucel; afami-cel) and expanded its indication to include patients ages 12 years and older with unresectable or metastatic synovial sarcoma whose disease has progressed after chemotherapy. Eligible patients must be positive for HLA-A*02:01, -A*02:02, -A*02:03, or -A*02:06 and have tumors that express the MAGE-A4 antigen.

The Role of Rusfertide in Decreasing Phlebotomies in Patients With Polycythemia Vera by Madaline Spencer| Published on: Jul 1, 2026

The Role of Rusfertide in Decreasing Phlebotomies in Patients With Polycythemia Vera by Madaline Spencer| Published on: Jul 1, 2026 Andrew Kuykendall, MD, Clinical Researcher at Moffitt Cancer Center, discusses the role of rusfertide in decreasing phlebotomies in patients with polycythemia vera (PV). https://checkrare.com/the-role-of-rusfertide-in-decreasing-phlebotomies-in-patients-with-polycythemia-vera/

Congenital Adrenal Hyperplasia by CheckRare Staff| Updated on: Jul 1, 2026

https://checkrare.com/congenital-adrenal-hyperplasia/ Congenital adrenal hyperplasia (CAH) is a group of rare autosomal, recessive genetic disorders that impair production of cortisol (also known as hydrocortisone).[1,2] The hypothalmus and pituitary gland are prompted to overproduce corticotropin-releasing hormone (CRH) and adrenocorticotrophic hormone (ACTH), causing an abnormal enlargement of the adrenal gland and accumulation of cortisol precursors produced by the adrenal gland.[1] With the inability to convert these precursors to cortisol, the body converts them to androgens (i.e., male hormones) instead, resulting in excess androgen concentrations.[3]

Spinal Muscular Atrophy: The Changing Definition of Success by CheckRare Staff| Published on: Jul 1, 2026

Spinal Muscular Atrophy: The Changing Definition of Success by CheckRare Staff| Published on: Jul 1, 2026 An Expert Panel on the Evolution of SMA Care Spinal muscular atrophy (SMA) has undergone a remarkable transformation over the past decade. Drs. Nancy Kuntz, Alicia Henriquez, and Angela Lek discuss how advances in disease-modifying therapies have fundamentally changed the outlook for children living with SMA, leading clinicians to rethink what constitutes a successful outcome in SMA care. https://checkrare.com/spinal-muscular-atrophy-the-changing-definition-of-success/

Are All Cancers Rare Cancers? The Need for Better Classification Systems by Madaline Spencer| Published on: Jul 2, 2026

Are All Cancers Rare Cancers? The Need for Better Classification Systems by Madaline Spencer| Published on: Jul 2, 2026 Chadi Nabhan, MD, Hematologist and Oncologist, Chief Medical Officer at Ryght AI, and Vivek Subbiah, MD, Professor of Medicine at Stanford University and Executive Medical Director of Novel Therapies & Clinical Trial Network at Stanford Health Care, discuss the need for better classification systems in precision oncology. https://checkrare.com/are-all-cancers-rare-cancers-the-need-for-better-classification-systems/

FDA Approves Lumvoa (Veligrotug) for Thyroid Eye Disease by Madaline Spencer| Published on: Jul 3, 2026

https://checkrare.com/fda-approves-lumvoa-veligrotug-for-thyroid-eye-disease/ The US Food and Drug Administration (FDA) has approved Lumvoa (veligrotug) for the treatment of thyroid eye disease (TED), regardless of TED’s duration or activity. TED is a chronic endocrine, autoimmune disease characterized by immune-mediated orbital inflammation that greatly impacts a person’s vision. The condition often occurs in people with hyperthyroidism or Graves’ disease, but also can occur in association with hypothyroidism, euthyroidism, and Hashimoto’s thyroiditis. Graves’ disease affects approximately 1% to 2% of the adult population, with an estimated 40% of patients subsequently developing TED over the course of their lifetime. The onset of TED typically occurs between 30 and 50 years of age, with the disease course more severe after the age of 50. Common symptoms can include ocular discomfort, upper eyelid retraction, dry eyes, tearing, inflammation, erythema, light sensitivity, and sensation of a foreign body present in the eye.

Beyond the Update in Advanced/Recurrent Endometrial Cancer: How Evidence Is Shaping New Guidelines Authors: Nicole Concin, MD, PhD; Els Van Nieuwenhuysen, MD, PhD; Xavier Matias-Guiu, MD, PhD

https://www.medscape.org/viewarticle/beyond-update-advanced-recurrent-endometrial-cancer-how-2026a10006up?page=1&src=mkmcmr_driv_stan_mscpedu_260630-OUS-HONC-beyond-update-advanced-recurrent-endometrial-cancer-how-2026a10006up-cta&uac=148436CN

Historic moments The Lancet Oncology +...

Historic moments The Lancet Oncology https://www.thelancet.com/journals/lanonc/issue/vol27no7/PIIS1470-2045(26)X2006-X

Safe and equitable medical radiation in the Asia–Pacific The Lancet Regional Health – Western Pacific +...

Safe and equitable medical radiation in the Asia–Pacific The Lancet Regional Health – Western Pacific https://www.thelancet.com/journals/lanwpc/issue/vol71nonull/PIIS2666-6065(26)X2004-1

NIH's All of Us Research Program is now the largest integrated genomics and health database in the world

NIH's All of Us Research Program is now the largest integrated genomics and health database in the world Data from more than 747,000 participants is now available to scientists, powering next-generation discoveries in precision medicine. The National Institutes of Health (NIH) has issued the most expansive data release in the history of its All of Us Research Program, making available data from more than 747,000 participants and establishing All of Us as the world’s largest integrated genomic and electronic health record (EHR) database. The latest data release includes more than 535,000 whole genome sequences linked to nearly 482,000 electronic health records, a combination of genomic depth and clinical breadth unmatched by any research program in the world. https://www.nih.gov/news-events/news-releases/nihs-all-us-research-program-now-largest-integrated-genomics-health-database-world

Charting New Frontiers in Advanced Breast Cancer: Milestones, Missions, and Mastery Authors: Paolo Tarantino, MD, PhD; Kevin Kalinsky, MD, MS, FASCO; Sibylle Loibl, MD, PhD

https://www.medscape.org/viewarticle/charting-new-frontiers-advanced-breast-cancer-milestones-2026a1000fu7?page=1&src=mkmcmr_driv_stan_mscpedu_260704-OUS-HONC-charting-new-frontiers-advanced-breast-cancer-milestones-2026a1000fu7-cta&uac=148436CN

New Alzheimer’s blood test may tell when symptoms are around the corner A novel biomarker beats the leading diagnostic blood test at predicting disease progression.

New Alzheimer’s blood test may tell when symptoms are around the corner A novel biomarker beats the leading diagnostic blood test at predicting disease progression. Small loops of genetic material may be strong indicators of imminent Alzheimer’s disease (AD) symptoms. In a National Institutes of Health (NIH)-funded study, researchers showed that elevated levels of certain circular RNAs (circRNAs) in the blood nearly tripled patients’ risk of developing symptoms, suggesting these molecules are more sensitive to symptom onset than traditional AD biomarkers. https://www.nih.gov/news-events/news-releases/new-alzheimers-blood-test-may-tell-when-symptoms-are-around-corner

About World Hepatitis Day

https://www.cdc.gov/hepatitis-awareness/about/world-hepatitis-day.html?utm_medium=email&utm_source=govdelivery Viral hepatitis affects more than 300 million people worldwide and leads to more than 1 million deaths each year. Despite effective vaccines, prevention strategies, and medications, deaths from hepatitis are increasing globally. CDC and other organizations around the world recognize WHD by raising awareness about viral hepatitis, the burdens people with hepatitis face, ongoing work to combat viral hepatitis across the globe, and actions people can take to prevent future transmission.

The USA at 250: science in the new gilded age The Lancet ++... +

The USA at 250: science in the new gilded age The Lancet https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)01333-4/fulltext?dgcid=raven_jbs_etoc_email Jul 04, 2026 Volume 408Number 10549p1-92 https://www.thelancet.com/journals/lancet/issue/vol408no10549/PIIS0140-6736(26)X2024-4 Combined bladder–kidney transplantation: first-in-human feasibility trial Nima Nassiri, MDa Send email to nnassiri@mednet.ucla.edu ∙ Inderbir S Gill, MD https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00718-X/abstract?dgcid=raven_jbs_etoc_feature_lancet

Most Read Cancer Science & Oncogenesis +...

https://read.qxmd.com/collection/1133?ecd=wnl_readmost_260703

HER2-Positive Early Breast Cancer: What the Latest Data Mean for Your Practice Authors: Judy King, MRCP, PhD; Charles Geyer, MD

https://www.medscape.org/viewarticle/her2-positive-early-breast-cancer-what-latest-data-mean-your-2026a10002fg?page=1&src=mkmcmr_driv_stan_mscpedu_260703-OUS-HONC-her2-positive-early-breast-cancer-what-latest-data-mean-your-2026a10002fg-cta&uac=148436CN

Steps for Personalized and Collaborative Decision-Making in HER2-Mutated NSCLC Authors: Pasi Jänne, MD, PhD, FASCO; Soo-Ryum (Stewart) Yang, MD; Xiuning Le, MD, PhD

https://www.medscape.org/viewarticle/steps-personalized-and-collaborative-decision-making-her2-2026a10007ur?page=1&src=mkmcmr_driv_stan_mscpedu_260703-OUS-HONC-steps-personalized-and-collaborative-decision-making-her2-2026a10007ur-cta&uac=148436CN

The great imitator - and the great instigator - of invisible illness

The great imitator - and the great instigator - of invisible illness Understanding Lyme Disease, Supporting Patients, Advancing SolutionsWhat is Lyme Disease? Lyme disease is a tick-borne infection that can lead to chronic, often invisible multi-system illness. Even after treatment, up to 20% of patients may develop Lyme “infection-associated chronic conditions and illnesses” (Lyme-IACCI) with persistent fatigue, pain, cognitive issues, neurological complications, and other enduring health challenges. https://www.hhs.gov/lyme/index.html?utm_medium=email&utm_source=govdelivery HHS announced a series of major initiatives to strengthen the nation’s response to Lyme disease and other tick-borne illnesses. HHS actions include a multi-million-dollar pilot program focused on tick control, up to $2.5 million in innovation challenges, funding for NIH researchers to combat Alpha-gal syndrome, and a public-private collaboration to help patients connect with experienced providers. What is Lyme Disease? Lyme disease is a tick-borne infection that can lead to chronic, often invisible multi-system illness. More than 476,000 Americans are diagnosed with Lyme disease each year. Even after treatment, up to 20% of patients may develop Lyme “infection-associated chronic conditions and illnesses” (Lyme-IACCI) with persistent fatigue, pain, cognitive issues, neurological complications, and other enduring health challenges. What is Alpha-gal? Alpha-gal syndrome (AGS), a tick-associated condition that can trigger potentially serious allergic reactions to red meat and other mammalian products. The CDC estimates, nearly 500,000 Americans are living with AGS, though emerging evidence suggests the true number may be significantly higher.

Trauma-focused therapy integrated with cognitive behavioural therapy for psychosis for people with post-traumatic stress disorder and psychosis (the STAR trial): a multicentre, pragmatic, randomised trial in the UK

Trauma-focused therapy integrated with cognitive behavioural therapy for psychosis for people with post-traumatic stress disorder and psychosis (the STAR trial): a multicentre, pragmatic, randomised trial in the UK Prof Emmanuelle Peters, PhDa,b Send email to emmanuelle.peters@kcl.ac.uk ∙ Sarah Swan, DClinPsya,b ∙ Raphael Underwood, PhDa,b ∙ Hassan Jafari, PhDc ∙ Prof Filippo Varese, PhDd,e ∙ Prof Craig Steel, PhDg,h ∙ et al. https://www.thelancet.com/journals/lanpsy/article/PIIS2215-0366(26)00090-8/fulltext?dgcid=hubspot_update_feature_updatealerts_lanpsy&utm_campaign=update-lanpsy&utm_medium=email&_hsenc=p2ANqtz--wfnTMopGC9GTMf_UXQW1-AaA443sc08ajs_QYHWlpHXAUaLlE9vKm23AAqJu5KGlzjYpsc8SZBZOYCBPmlpgrC-extw&_hsmi=426493445&utm_content=426443511&utm_source=hs_email

Relationships between cannabis use and mental disorders: assessing the coherence of evidence from studies with different methodologies

Relationships between cannabis use and mental disorders: assessing the coherence of evidence from studies with different methodologies Prof Wayne Hall, PhDa Send email to w.hall@uq.edu.au ∙ Tesfa M Yimer, PhDa ∙ Rachel Lees Thorne, PhDb ∙ Prof Eva Hoch, PhDc,d,e ∙ Chloe Burke, PhDb,f ∙ Ad Gridleyg ∙ et al. https://www.thelancet.com/journals/lanpsy/article/PIIS2215-0366(26)00086-6/fulltext?dgcid=hubspot_update_feature_updatealerts_lanpsy&utm_campaign=update-lanpsy&utm_medium=email&_hsenc=p2ANqtz--08pZNXXlvYLAx0DxS6YRJTkxQ4PUOknthwP4bWSEDpxN2bknzMfDIERXbFloI051e0UV2PpCx_u7C-cGeGgTU1Zc4qQ&_hsmi=426493445&utm_content=426443511&utm_source=hs_email

International cannabis policies and their association with cannabis use, cannabis use disorder, and other psychiatric disorders

International cannabis policies and their association with cannabis use, cannabis use disorder, and other psychiatric disorders Prof Tom P Freeman, PhDa Send email to t.p.freeman@bath.ac.uk ∙ Rachel Lees Thorne, PhDa ∙ Elle Wadsworth, PhDa ∙ Tara Carney, PhDb,c,d ∙ Alvaro Castillo-Carniglia, PhDe,f ∙ Prof Magdalena Cerdá, DrPHg ∙ Rasmon Kalayasiri, MDh ∙ Prof Beau Kilmer, PhDi ∙ Prof Valentina Lorenzetti, PhDj,k ∙ Jakob Manthey, PhDl,m ∙ Daniel T Myran, MDn,o,p ∙ Ariadne Rivera-Aguirre, PhDf,g ∙ Marta Rychert, PhDq ∙ Jack Wilson, PhDr ∙ Tesfa Yimer, PhDs ∙ Prof Wayne Hall, PhD https://www.thelancet.com/journals/lanpsy/article/PIIS2215-0366(26)00087-8/abstract?utm_campaign=update-lanpsy&utm_medium=email&dgcid=hubspot_update_feature_updatealerts_lanpsy&_hsenc=p2ANqtz-8ul4ZtXXy7Ns1unIenbvgCyHkEXdo7uP-oP7mUHv-iwDTR3kW88SutraflW0-TUExzvRE-nhQsE6QoCgOBJFeBvgoGLQ&_hsmi=426493445&utm_content=426443511&utm_source=hs_email

Editorial p531 Glimmers of hope in times of war The Lancet Psychiatry +...

Editorial p531 Glimmers of hope in times of war The Lancet Psychiatry https://www.thelancet.com/journals/lanpsy/issue/vol13no7/PIIS2215-0366(26)X2005-3

Study maps domestic violence perpetrator interventions across the Indo-Pacific

https://www.news-medical.net/news/20260702/Study-maps-domestic-violence-perpetrator-interventions-across-the-Indo-Pacific.aspx Domestic and family violence (DFV) rates in the Indo-Pacific are among the highest globally, but there is a lack of focus, both in research and policy, on the issue across the region. In the first analysis of its kind centered on the Indo-Pacific, Griffith University researchers conducted a scoping review, mapping the intervention programs that existed for male perpetrators of DFV, examining what they looked like in practice, and where opportunities for learning and collaboration lay. Dr Freya McLachlan, Research Fellow at the Center of Ex...

Overlooked parasitic disease linked to HIV and cervical cancer risk

https://www.news-medical.net/news/20260703/Overlooked-parasitic-disease-linked-to-HIV-and-cervical-cancer-risk.aspx New research from Liverpool School of Tropical Medicine (LSTM) has highlighted the need to test millions of women and girls for female genital schistosomiasis (FGS), a neglected disease that can increase the risk of chronic illness, HIV and cervical cancer.

Can ibuprofen improve drug-resistant tuberculosis treatment?

https://www.news-medical.net/news/20260703/Can-ibuprofen-improve-drug-resistant-tuberculosis-treatment.aspx Could a common over-the-counter anti-inflammatory drug become a new weapon against drug-resistant tuberculosis? Early findings suggest immune benefits, but larger trials are needed to determine whether these translate into improved patient outcomes. Adding ibuprofen to standard treatment for highly drug-resistant tuberculosis did not improve clinical outcomes in a pilot trial, although the anti-inflammatory drug showed signs of reducing inflammation, according to a study published in Nature Communications.

What Are Neuropeptides and Why Are They Important?

https://www.news-medical.net/health/Neuropeptides-explained-How-brain-chemical-signals-affect-health.aspx From mood and memory to pain and appetite, neuropeptides reveal how tiny chemical signals can have wide-reaching effects on human health. Within the brain, neurons produce neuropeptides to regulate emotion, pain, metabolism, and the immune response. Rather than acting only locally, neuropeptides can signal through synapses, diffuse through extracellular space, or act as circulating hormone-like messengers, producing effects that often last from seconds to minutes

Synthetic Human Chromosomes Explained

https://www.news-medical.net/health/Synthetic-Human-Chromosomes-Explained.aspx From synthetic chromosomes and recoded genomes to next-generation gene therapies and engineered cells, discover how genome-scale engineering is redefining the possibilities of biology while reshaping the future of medicine and biotechnology. Synthetic genomics is a specialized branch of synthetic biology characterized by the de novo design, chemical synthesis, assembly, and functional activation of complete genomes or chromosomes to create living viruses or cells. In addition to synthetic microbial genomes, modern genome engineering increasingly focuses on chromosome-scale manipulation, including synthetic yeast chromosomes, human artificial chromosomes (HACs), genome recoding, chromosome fusion, and designer genomes with altered biological properties.1,2,4 Recent advances in genome engineering technologies have enabled the rational design or modification of chromosomal architecture to elicit specific desirable phenotypes, such as viral resistance or customized metabolic pathways.

What Your Earwax Says About Your Health

From odor changes to wax texture, cerumen is emerging as a small but information-rich signal of ear health, infection, and future diagnostic possibilities. https://www.news-medical.net/health/What-Your-Earwax-Says-About-Your-Health.aspx Cerumen, commonly known as earwax, has historically been considered a physiological byproduct that requires periodic removal. In most people, however, the ear canal is self-cleaning, and routine mechanical removal is unnecessary unless wax causes symptoms or prevents examination.2,8 However, emerging research indicates that the composition of cerumen may provide valuable insights into metabolic activity, microbiome status, and systemic health.1 Visible changes in wax should therefore be interpreted as clinical clues rather than stand-alone diagnostic findings

Ongoing Perspectives in HER2-Mutated Advanced NSCLC: An Expert Viewpoint on the Latest Data Authors: Helena Yu, MD

https://www.medscape.org/viewarticle/ongoing-perspectives-her2-mutated-advanced-nsclc-expert-2026a10001va?page=1&src=mkmcmr_driv_stan_mscpedu_260702-OUS-HONC-ongoing-perspectives-her2-mutated-advanced-nsclc-expert-2026a10001va-cta&uac=148436CN

What ASCO 2026 Taught Us About Scaling AI in Cancer Care Arturo Loaiza-Bonilla, MD, MSEd +++

https://www.medscape.com/viewarticle/what-asco-2026-taught-us-about-scaling-ai-cancer-care-2026a1000l9c?ecd=wnl_edit_tpal_etid8474756&uac=148436CN&impID=8474756 A woman completes human papillomavirus (HPV) self-collection in a community clinic, receives an abnormal result, and then disappears into the space between screening and treatment. Avoid These Legal Pitfalls When Using AI Scribes Ericka L. Adler, JD, LLM https://www.medscape.com/viewarticle/avoid-these-legal-pitfalls-when-using-ai-scribes-2026a1000lp6?ecd=wnl_edit_tpal_etid8474756&uac=148436CN&impID=8474756 UV Misinformation on Social Media: What Can Dermatologists Do? Sara Freeman https://www.medscape.com/viewarticle/uv-misinformation-social-media-what-can-dermatologists-do-2026a1000mg1?ecd=wnl_edit_tpal_etid8474756&uac=148436CN&impID=8474756

How to stay safe and healthy during extreme heat Tips for surviving a heat wave July 2, 2026 VHA Public Health & VHA Office of Emergency Management ++++

https://news.va.gov/140948/how-to-stay-safe-healthy-during-extreme-heat/?utm_medium=email&utm_source=govdelivery Stay safe and healthy during extreme heat Temperatures above 90 degrees Fahrenheit for at least 2 days can lead to serious medical issues, medical emergencies, and even death. Follow these tips to prevent health problems and stay safe during extreme heat. Veteran with Multiple Sclerosis finds new motivation at VA Wheelchair Games July 1, 2026 https://news.va.gov/147870/veteran-multiple-sclerosis-wheelchair-games/?utm_medium=email&utm_source=govdelivery Carin Waslo, MPH VA Primary Care adds virtual reality to Veterans’ Mental Health Toolkit June 30, 2026 https://news.va.gov/147809/va-adds-virtual-reality-mental-health-toolkit/?utm_medium=email&utm_source=govdelivery Stacie Rivera Communications Specialist, Digital Health Office (DHO) A guide to help Veterans manage stressors that increase suicide risk June 30, 2026 https://news.va.gov/147812/guide-manage-stressors-increase-suicide-risk/?utm_medium=email&utm_source=govdelivery Christopher Maxwell Director of Communications, Outreach, and Events, Office of Suicide Prevention

Ebola outbreak: why haematology matters The Lancet Haematology +...

Ebola outbreak: why haematology matters The Lancet Haematology https://www.thelancet.com/journals/lanhae/issue/vol13no7/PIIS2352-3026(26)X2006-3

The Future of Endometrial Cancer Pathology InDiscussion Endometrial Cancer Show Image Ursula A. Matulonis, MD; Marisa R. Nucci, MD

https://www.medscape.com/ca8/p04/podcast-endometrial-cancer-s3-ep5-2026a10006if?src= Drs Ursula A. Matulonis and Marisa R. Nucci discuss the future of AI and pathology and how genetics and genomics play a role in the diagnosis of endometrial cancer.

Fast Five Quiz: Melanoma Adjuvant Treatment Reviewed by Adil I. Daud, MD ++

Fast Five Quiz: Melanoma Adjuvant Treatment Reviewed by Adil I. Daud, MD https://reference.medscape.com/viewarticle/melanoma-adjuvant-treatment-2025a1000z67?_gl=1*7ttryj*_gcl_au*NjkzMDY5MjIxLjE3ODA2NzA2MDAuMTYwNjY1Nzg3Mi4xNzgzMDgzNjM1LjE3ODMwODM3MjM. Surgery is the primary treatment for cutaneous melanoma. Standard management consists of wide local excision and regional lymph node staging with sentinel lymph node biopsy. Many patients continue to have a significant risk for recurrence, even in cases of lymph node-negative melanoma, which necessitates further adjuvant treatment beyond surgery. Fast Five Quiz: Melanoma Treatment Reviewed by Adil I. Daud, MD https://reference.medscape.com/viewarticle/fast-five-quiz-melanoma-treatment-2025a1000dry?_gl=1*4au3mb*_gcl_au*NjkzMDY5MjIxLjE3ODA2NzA2MDAuMTYwNjY1Nzg3Mi4xNzgzMDgzNjM1LjE3ODMwODM3MjM. The global incidence of melanoma, a potentially lethal form of skin cancer, has continued to rise. Malignant melanoma is diagnosed in both older and younger populations, and it is one of the leading cancers in average years of life lost per death from disease. If current trends continue, the annual global burden is projected to reach 96,000 deaths and roughly 510,000 new cases by 2040.

Psoriasis: Can Gut Biotics Improve Treatment? Luis Quevedo

https://www.medscape.com/viewarticle/psoriasis-can-gut-biotics-improve-treatment-2026a1000mha?ecd=WNL_trdalrt_pos1_ous_260703_etid8475286&uac=148436CN&impID=8475286 Psoriasis is a chronic immune-mediated inflammatory skin disease that affects approximately 2% of the global population, or an estimated 40-160 million individuals, with about 4 million new cases diagnosed annually. Although the precise cause remains unclear, researchers believe that genetic susceptibility, systemic inflammation, and gut microbiota dysbiosis all contribute to disease development.

Transforming Care: Case Studies and Treatment Advances in Multiple Myeloma Authors: Beth Faiman, PhD, MSN, APN-BC, AOCN®, TCTCN®, FAAN, FAPO; Teresa Miceli, RN, BSN, OCN; Tiffany Richards, PhD, ANP-BC, AOCNP®; Donna D. Catamero, ANP-BC, OCN®, CCRC

https://www.medscape.org/viewarticle/sharing-decision-treatment-planning-high-risk-hr-her2-early-2026a1000f67?page=1&src=mkmcmr_driv_stan_mscpedu_260703-OUS-HONC-sharing-decision-treatment-planning-high-risk-hr-her2-early-2026a1000f67-cta&uac=148436CN

Sharing the Decision of Treatment Planning in High-Risk HR+/HER2- Early Breast Cancer Authors: Shaheenah Dawood, MBBCh, MPH, FACP

https://www.medscape.org/viewarticle/sharing-decision-treatment-planning-high-risk-hr-her2-early-2026a1000f67?page=1&src=mkmcmr_driv_stan_mscpedu_260703-OUS-HONC-sharing-decision-treatment-planning-high-risk-hr-her2-early-2026a1000f67-cta&uac=148436CN

Dying with Dignity—time to cut the red tape The Lancet Respiratory Medicine +...

https://www.thelancet.com/journals/lanres/issue/vol14no7/PIIS2213-2600(26)X2006-9

“A world on the edge” as preparedness hopes waver The Lancet Microbe +...

https://www.thelancet.com/journals/lanmic/issue/vol7no7/PIIS2666-5247(26)X2006-7

Editorial e483 Sex and gender dimensions of pain The Lancet Obstetrics, Gynaecology, & Women's Health +...

https://www.thelancet.com/issue/S3050-5038(26)X2005-2

Editorial Digital demands for chronic disease research and management The Lancet Digital Health +...

https://www.thelancet.com/journals/landig/issue/vol8no5/PIIS2589-7500(26)X2005-2

Editorial p533 Bearing metabolism in mind: towards integrated care The Lancet Diabetes & Endocrinology +...

https://www.thelancet.com/journals/landia/issue/vol14no7/PIIS2213-8587(26)X2005-8

Editorial p615 Making neurology care transitions work for young patients The Lancet Neurology +...

https://www.thelancet.com/journals/laneur/issue/vol25no7/PIIS1474-4422(26)X2005-1

Why animal models still matter in drug development Patient advocates warn that political momentum to reduce animal testing is outpacing the scientific validation of alternative methods. Written byBree Foster, PhD

https://www.drugdiscoverynews.com/why-animal-models-still-matter-in-drug-development-17275 Governments around the world are moving to reduce the use of animal models in preclinical research, driven by ethical concerns and rapid advances in new approach methodologies (NAMs). In the US, this transition has been accelerated by recent legislative changes. The FDA Modernization Act 2.0, enacted in 2022, removed the decades-old statutory requirement that animal testing be included in Investigational New Drug applications. Three years later, FDA Modernization Act 3.0 went further, directing the FDA to establish a formal process for qualifying nonclinical testing methods.

Reengineering cancer vaccines for durable immune memory Therapeutic cancer vaccines are being reengineered to deliver stronger immune activation and longer-lasting protection against disease recurrence. Written byBree Foster, PhD

https://www.drugdiscoverynews.com/reengineering-cancer-vaccines-for-durable-immune-memory-17293?utm_campaign=DDN_Newsletter_Dose&utm_medium=email&_hsenc=p2ANqtz-_w6QR66mPoj9xCFxCKflFWaGdfRHmWRG_Ievh3ZnNTiVHMxpnSvjWRmgW9TEN0ZBwRL6DIyuhz4ldcKfXjaQBn_DB72g&_hsmi=426335944&utm_content=426335944&utm_source=hs_email When most people think of vaccines, they think of prevention — an injection that trains the immune system to produce antibodies against infectious diseases such as measles or polio. However, cancer vaccines are different. Rather than preventing disease, cancer vaccines are a type of immunotherapy designed to stimulate the immune system to attack cancer cells that are already present in the body. However, they have historically struggled to deliver consistent clinical benefit.

Colorectal cancer rates are rising in young people. What does that mean for detection and surgical treatment options?

https://www.linkedin.com/pulse/colorectal-cancer-rates-rising-young-people-nucac/ Diagnostic and surgical approaches to treating the disease are evolving—just as rates are spiking. Here’s how the surgical landscape will continue to shift alongside the alarming trend. Back in 2004, Shekar Narayanan, M.D., a colorectal cancer surgeon, treated a 21-year-old woman with early stage colorectal cancer. The patient had a minimally invasive procedure to remove a tumor a few years earlier, but the cancer had returned. Back then, colorectal cancer was considered rare in young adults, so it was common to take a more conservative approach to staging and treatment in this age group. Dr. Narayanan performed a colectomy—an invasive procedure in which a large part of the colon is removed—and created a colostomy, requiring the young patient to use a colostomy bag. Just three years later, at age 24, the cancer had metastasized. By age 25, the patient had died. Treatment for colorectal cancer has come a long way since then. Today, says Dr. Narayanan, that patient would have likely had her lymph nodes removed and examined at the outset instead of relying on a minor surgical procedure. But despite these advances in understanding and treatment, there’s still a long way to go: Colorectal cancer is steadily rising among people in their 20s and 30s, and colorectal cancer surgeons like Dr. Narayanan are screening, testing and treating more young adults than ever before.1 And while diagnostic and treatment approaches continue to advance, the rising rates mean that innovation is crucial to keep pace.